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INTRODUCTION
WIV-ISP is responsible for the diagnosis and surveillance of numerous microbial 
diseases. Therefore, microbial isolates should be characterised at a level suitable for 
routine surveillance, for outbreak detection and for tracing the source of an infection. 
In actual practice, this means for most pathogens that a subtyping technique is nee-
ded to allow characterisation below the serovar level. The development of molecular 
alternatives for classical microbiological subtyping methods allows for improvements in 
standardisation, accuracy and rapidity. The PhD project SalMolType, which is a collabo-
rative effort by the scientific unit Platform of Biotechnology and Molecular Biology and 
the Bacterial Diseases unit, aims at developing such a molecular alternative subtyping 
method and takes Salmonella phage typing as a case study.
Salmonella is one of the most frequent causes of food-borne outbreaks and human sal-
monellosis is the second most frequently reported zoonosis in the European Union (1). 
The most common serovars of Salmonella isolated from human outbreaks are Salmo-
nella enterica subsp. enterica serovar Enteritidis (S. Enteritidis) and Salmonella enterica 
subsp. enterica serovar Typhimurium (S. Typhimurium) (1). Typing methods which allow 
characterisation below the serovar level are essential in a surveillance programme for 
this diverse genus. Classical surveillance programmes for Salmonella rely on phenoty-
ping methods such as phage typing and antimicrobial susceptibility testing. Phage typing 
is a subjective technique that requires extensive experience to interpret the sensitivity of 
bacteria to bacteriophages. Its discriminatory power is often inadequate when it comes 
to finding the source of an infection, especially in countries where particular phage types 
are dominant; moreover, not-typable (NT) and reacts-but-does-not-conform (RDNC) iso-
lates limit the suitability of phage typing for surveillance and outbreak detection, since 
not all isolates can be subtyped by this technique (2-5). Nowadays, phage typing as a 
subtyping technique is often complemented with molecular methods like pulsed-field gel 
electrophoresis (PFGE). PFGE separates large DNA molecules, resulting from macro-
restriction of the genome, by gel electrophoresis with alternately pulsed electrical fields 
in different directions. Differences in the observed electrophoretic patterns can be used 
to discriminate between isolates. PFGE is considered as the gold standard for subty-
ping of Salmonella (6). Yet, recent studies suggest that multiple-locus variable-number 
of tandem repeats analysis (MLVA) improves surveillance, detection of outbreaks and of 
Salmonella infection sources, in particular for S. Typhimurium outbreaks (2;4;7;8). 
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MLVA targets rapidly evolving genomic elements known as tandem repeats. This allows 
them to be used in order to study genetic relatedness between isolates. The combina-
tion of the number of tandem repeats at a predefined number of MLVA loci results in a 
MLVA profile.
 
In Belgium, S. Typhimurium is, since 2006, the most frequently isolated serovar from hu-
mans, with an average of 1986 isolates reported per year (55.9% of all Salmonella isolates, 
average from 2006 up to 2012) (9). Hence, subtyping of this serovar is very important for 
outbreak detection and tracing outbreak sources. The Belgian National Reference Centre 
for Salmonella and Shigella (NRCSS) relies on phage typing and antimicrobial susceptibili-
ty testing for routine surveillance of S. Typhimurium, complemented with PFGE during out-
break investigations. PFGE is a labour-intensive and time-consuming technique and, the-
refore, implementation of this subtyping method for routine surveillance is not feasible for 
the Belgian NRCSS. MLVA, which requires less hands-on time and allows for faster typing 
and easy inter-laboratory comparison of results, has been adopted by several European 
countries for surveillance and detection and investigation of outbreaks (8) and is currently 
also used by the Belgian NRCSS. Nonetheless, a recent study (5) on phage type, antimi-
crobial susceptibility and MLVA of a large collection of S. Typhimurium collected in Belgium 
during 2010-2012 demonstrated that, although the discriminatory power of MLVA allowed 
for an improvement of public health surveillance, phage typing was still necessary for iso-
lates with a frequent MLVA profile to detect an outbreak and to uniquely characterise an 
outbreak isolate. Moreover, as some of the MLVA loci showed to be unstable, these genetic 
markers for subtyping should be interpreted with caution (5). An ideal subtyping technique 
would combine different typing methods into a single molecular assay with stable markers.
In this context, the PhD project SalMolType aims at developing a molecular subtyping tech-
nique, which should ideally be inexpensive, rapid, highly discriminative and robust and the 
used markers should be stable and testable in all isolates, so that a type can be assigned 
to all isolates (6;10-12).
Until now, different kinds of DNA markers have been studied, alone or combined, for their 
suitability in a molecular subtyping scheme for S. Typhimurium. The number of markers 
included in the resulting methods and the level of multiplexing still feasible often deter-
mines the discriminatory power and rapidity of the method (6).
In this study we discuss a proof-of-concept for a molecular subtyping method for S. Typhi-
murium that combines different types of markers, such as amplified fragment length poly-
morphisms (AFLP), prophage genomes, sequence repeats, antibiotic resistance markers 
and single-nucleotide polymorphisms (SNPs). To achieve a sufficient level of multiplexing 
in a high-throughput manner, we have implemented the Luminex® technology. This tech-
nology, which emerged in the 1990s, allows us to distinguish up to 500 different targets in 
one sample through its bead-based assays and offers possibilities in various fields of public 




S. Typhimurium isolates were selected from the collection of the Belgian NRCSS. The 
selection includes 100 isolates, of which 13 isolates from two outbreaks, with different 
combinations of phage type, antimicrobial resistance pattern and MLVA profile. Besides the 
most frequently occurring phage types over the past years in Belgium, i.e. DT12, DT104L, 
DT120, DT193, DT195 and U302, also phage types DT1, DT35, DT104a, DT138, DT208, 
U311 and one RDNC isolate are included. In total, these isolates cover 25 different antimi-
crobial resistance patterns and 51 distinct MLVA profiles. 
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DNA isolation
DNA was isolated by boiling a single colony from an overnight culture on LB agar in water. 
After centrifugation, the supernatant was stored at -20°C and used for further analysis.
Stability experiment
Stability of selected markers was evaluated in 31 S. Typhimurium isolates of the most 
frequent phage types in Belgium. A series of 50 passages, starting from a single colony, 
was performed. Glycerol stocks were made before each fifth passage and DNA was isola-
ted from cultures after the final passage (10).
Marker selection 
Markers were based on information found in literature. Markers that were considered infor-
mative through presence or absence were screened by PCR and gel electrophoresis on 
30 isolates of the most common phage types in Belgium. Those markers which were not 
present or absent in all 30 isolates and thus have discriminatory power, were selected for 
the Luminex® assay.
Bead-based nucleic acid assay selection
The Luminex® technology, which is implemented through a MAGPIX® platform in the 
SalMolType project, utilises polystyrene beads with a different colour code for each set. 
Each bead set can be coated with a different capture probe. Multiplexing is then achieved 
by combining different bead sets to analyse one sample. During analysis, the set to which 
the bead belongs is determined by measuring the red fluorescence signal from the bead. 
Afterwards, the presence of a hybridised target oligonucleotide is detected by measuring 
the green fluorescence signal on that target. Each bead-based assay should thus incor-
porate a fluorophore in the target oligonucleotide. At this stage, different possibilities exist. 
At the start of the project, three bead-based DNA assay formats, i.e. direct hybridisation, allele 
specific primer extension (ASPE) and ligation dependent amplification (LDA), were compa-
red with regard to usage possibilities, multiplexing capacity, workflow, optimisation and cost. 
The direct hybridisation assay (1) starts with a multiplex PCR with labelled primers, after 
which the products are hybridised to beads, to which capture probes have been previously 
coupled. If primers labelled with biotin are used, an incubation step with streptavidin-phy-
coerythrin (SAPE) is necessary before analysis on a Luminex platform.
In contrast to the xMAP® technology that is used in direct hybridisation assays, where self-
designed capture probes have to be attached to the beads, the xTAG® technology utilises 
beads with pre-coupled 24 bp anti-TAG-sequences. ASPE and LDA are built upon this tech-
nology and should integrate the complementary TAG-sequence in the target oligonucleotide. 
ASPE (2) commences with a multiplex PCR, after which the products are treated with 
ExoSAP-ITTM to degrade remaining primers and dNTPs. Target-specific probes with a 
TAG-sequence at 5’ are then annealed to the PCR product and extended with inclusion of 
biotin-dCTP. The ASPE products are analysed on a Luminex® platform after hybridisation 
to xTAG® beads and incubation with SAPE.
The first step in a LDA assay (3) (figure 1) is a multiplex ligation with a probe pair for each 
target. The upstream probe has a universal primer site, TAG-sequence and target-spe-
cific part; the adjacent downstream probe has a target-specific part and universal primer 
site. The second step comprises a singleplex PCR with universal primers, one of which 
is labelled. After hybridisation to xTAG® beads and an optional incubation with SAPE, the 
amplified ligation products are read out on a Luminex® platform.
HealtH and disease monitoring
Multiplex oligonucleotide design and in silico simulation of multiplex assays
For the design of probe pairs and primers for the multiplex liquid bead sus-
pension array and in silico simulation of multiplex assays, two commer-
cial software packages were compared, i.e. VisualOMPTM in combination 





Careful selection of markers is required to eliminate markers that would give the same 
result for all isolates tested in the assay and hence would not allow for discrimination 
between isolates.
After PCR screening of 30 isolates of phage types DT12, DT104L, DT120, DT193, DT195 
and U302, 34 literature-based markers, detecting AFLP fragments, prophage genomes, 
sequence repeats, Salmonella genomic island 1 (SGI1) and allantoin utilisation, were 
found to be informative.
Antibiotic resistance genes, SNPs, a marker detecting all Salmonella species and a marker 
specific to S. Typhimurium are also included in the current selection of markers.
Bead-based nucleic acid assay selection
To combine the selected markers in a multiplex liquid bead suspension array, three nucleic 
acid assay formats were considered. The advantages and disadvantages of the different 
bead-based nucleic acid assays are summarised in table 1. The LDA assay was chosen 
for development of a subtyping method for S. Typhimurium, since the multiplex step in this 
assay format is a ligation, which allows for a higher multiplex capacity and an addition of 
markers without redesign of the assay, in contrast to multiplex PCR. A LDA assay would 
thus be more modular than assays based on direct hybridisation or on ASPE. Additionally, 
the LDA does not require the use of neurotoxic tetramethylammonium chloride (TMAC) 
buffer, coupling of capture probes or optimisation of the hybridisation to Luminex® beads. 
Furthermore, the costs and total time to complete the assay were found to be acceptable.
Multiplex oligonucleotide design and in silico simulation of multiplex assays
Software that predicts melting temperatures, hybridisation structures and specificity for dif-
ferent types of oligonucleotides, and thereby simulating the multiplex assays in silico, can 
facilitate the design of multiplex assays by reducing the time and cost of experimentation. 
An extensive comparison was made between VisualOMPTM in combination with Thermo-
BLASTTM and PrimerPlex to identify the most suitable software package for multiplex oli-
gonucleotide design and in silico simulation of multiplex assays. The comparison between 
both software packages is summarised in table 2.
For multiplex oligonucleotide design and in silico simulation of multiplex assays, Visua-
lOMPTM in combination with ThermoBLASTTM was selected, despite of the annual li-
cence fee, since it allows for the design of LDA probes, takes secondary structure fol-
ding into account and displays simulation results in easily interpretable graphics. 
 
Proof-of-concept of a molecular LDA subtyping assay
Out of the 34 markers found informative through PCR screening, 10 markers with high 
discriminatory power—including AFLP, prophages, sequence repeats and SGI1—were 
selected for a proof-of-concept for the LDA subtyping assay. Two markers, one detecting 
all Salmonella species and the other specific to S. Typhimurium, were included as internal 
control for the DNA templates. Also included in the proof-of-concept are three markers for 
antibiotic resistance genes and one SNP.
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The resulting 16-plex LDA was applied to 100 isolates and the 31 isolates after 50 pas-
sages in the stability experiment. The amplified ligation products were read out on a 
MAGPIX® platform. Each assay included a negative control (containing all reagents but 
no DNA template, for background signal measurement) and a positive control (contai-
ning all reagents and a mixture of DNA template representing all 16 markers) to verify 
the reaction. A clear separation was observed between negative and positive signals, 
measured as median fluorescence intensity (MFI).
Presence or absence of these 16 markers, as detected by the LDA, resulted in 20 distinct 
profiles in the 131 tested isolates. Inconsistencies between results of the PCR screening 
on 30 S. Typhimurium isolates and results of LDA were resolved by sequencing of the 
PCR product. The isolates in the stability experiment gave an identical profile before and 
after the 50 serial passages in LB medium.
Eleven LDA profiles were observed for a single isolate only. The eight DT1 isolates in-
cluded in this study showed three different LDA profiles, which were not observed for 
other analysed isolates. Discrimination within isolates of the same phage type was also 
observed for isolates harbouring other phage types, including DT104. The LDA also al-
lowed us to discriminate between isolates presenting the same MLVA profile. DT193 iso-
lates presenting 2, 3 or 4 repeats at MLVA locus STTR9 showed distinct LDA profiles; the 
profile of the isolate with four repeats was not shared with other isolates. For DT12, dif-
ferent LDA profiles were also observed for isolates with 2, 3 or 5 repeats at STTR9. This 
shows that the discriminatory power of the proof-of-concept assay is already reasonable.
However, within clusters of isolates with the same LDA profile, seven clusters included 
two or more phage types and two or more MLVA profiles. The outbreak isolates showed 
the same LDA profile, but this LDA profile was also shared with other unrelated isolates, 
which have a different combination of phage type and MLVA profile than the outbreak 
isolates.
These findings necessitated extending the LDA assay with more informative markers to a 
higher level of multiplexing. Since the delivery of the proof-of-concept, the general expe-
rimental workflow has been used to include 37 additional literature-based markers in the 
subtyping assay so that the discriminatory power has considerably increased. Screening 
of a large collection of S. Typhimurium is currently ongoing, to evaluate the capabilities 
of this novel subtyping assay. Next-generation sequencing (NGS) of S. Typhimurium 
isolates and genome comparison is also ongoing, to increase the number of informative 
molecular markers for further fine tuning of the developed subtyping method.
DISCUSSION
Subtyping of foodborne pathogens is necessary for public health surveillance, out-
break detection and tracing of outbreak sources. Classically in surveillance, isolates 
of Typhimurium are phage typed and, often in case of an outbreak, further subtyped 
using molecular techniques such as PFGE or MLVA. Even if these techniques pres-
ent undoubted additional value for subtyping, each of them has its intrinsic disad-
vantages. For this reason scientists are still searching for another subtyping method, 
which should ideally be inexpensive, rapid, highly discriminative and robust (6;12). 
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Many of the proposed alternative molecular methods for subtyping of S. Typhimurium are 
limited by the number of molecular markers and by the capacity of multiplexing those mar-
kers in a single run. The Luminex® technology offers a multiplex capacity of 500 markers 
in a single run and has already been applied in different stages of Salmonella surveillance, 
but none of them fully meets the requirements of an optimal (sub)typing method. The com-
mercial xMAP® Salmonella Serotyping Assay allows for characterisation of 90% of the 
most common Salmonella up to the serovar level, but is too expensive and interpretation 
of the results is too complex for routine use. At the subtyping level, i.e. below the serovar 
level, two assays have been published so far for S. Typhimurium, to our knowledge. The 
first assay uses two multiplex PCRs to analyse 30 prophage-related markers in a direct 
hybridisation assay (13). Analysis of 438 S. Typhimurium isolates showed that the dis-
criminatory power was not yet sufficient, since the assay assigned the same prophage 
profile to isolates with different phage types. The second Luminex® subtyping assay is the 
CRISPOL assay (14), which stands for clustered regularly interspaced short palindromic 
repeats (CRISPR) polymorphisms. Here, a direct hybridisation assay is used for detection 
of 72 CRISPR spacers, after amplification of the spacer content of two CRISPR loci in 
a singleplex PCR. The CRISPOL assay was however not able to discriminate between 
S. Typhimurium isolates with phage type DT104, so that yet another subtyping method, 
e.g. MLVA, is needed for these isolates.
In the SalMolType project the LDA assay, which can achieve a high level of multiplexing 
by separating detection and amplification, was selected for development of a molecular 
alternative to traditional microbiological subtyping techniques. LDA is also cost-effective 
since the specific probe pairs are unlabelled. Numerous types of molecular markers can 
be combined and straightforwardly added or left out of the assay. New probe pairs are 
assigned a different TAG for detection on the Luminex® platform, while still using the uni-
versal primer pair for amplification of the signal, which makes the LDA a modular assay. 
This was particularly interesting in our case, as it was necessary to include additional infor-
mative markers to our proof-of-concept assay in order to increase its discriminatory power. 
Indeed, although discrimination within isolates of the same phage types was observed, 
even for isolates belonging to phage type DT104, which are difficult to type with PFGE 
(15), different phage types and different MLVA profiles were observed in clusters showing 
the same LDA profile. Epidemiological concordance could also not be proven with the 
initial proof-of-concept assay, since the outbreak isolates did show the same LDA profile, 
but the LDA profile was shared with other, unrelated isolates. However, these results for 
the outbreak isolates were also observed for phage typing and for MLVA (5) and, as a 
consequence, the outbreak isolates could only be distinguished by the combination of 
phage type and MLVA profile. Extension of our proof-of-concept assay with other informa-
tive probe pairs, including these covering SNPs, should solve this issue. In fact, LDA is 
very specific due to severe constraints on the ligation reaction: the upstream probe must 
anneal adjacent to the downstream probe and a strict complementarity is necessary for 
the base pairs flanking the ligation site. The strict complementarity allows straightforward 
detection of SNPs.
An additional advantage of the Luminex® technology is that processing of the results gene-
rated by the LDA assay is facilitated by the single file output of the MAGPIX® platform, 
which can easily be handled without the need of expensive software. This will simplify the 
implementation of this assay in routine surveillance.
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CONCLUSIONS
We have presented a proof-of-concept for the use of a LDA assay with analysis on a 
MAGPIX® platform for the subtyping of S. Typhimurium. More markers, based on litera-
ture and on NGS, have been included to increase discriminatory power, while optimisa-
tion of the workflow and of the assay has further reduced cost and time. This will lead to 
a cost-effective, rapid, highly discriminative, known target-based and robust method with 
stable markers, more efficiently addressing the needs of S. Typhimurium subtyping than 
MLVA and phage typing.
IMPACT ON PUBLIC HEALTH
Rapid and accurate subtyping of pathogens is important for surveillance and is crucial in 
determining the link between food and a human isolate and for the timely confinement 
of an outbreak. New molecular techniques offer an improvement in terms of standardi-
sation, speed and accuracy with respect to conventional microbiological techniques. In 
the SalMolType project, an alternative method for subtyping of S. Typhimurium is deve-
loped, which is highly needed to tackle the disadvantages of the currently used subtyping 
methods.
Additionally, the project has a double multiplier effect for public health. On the one hand, 
it proposes a workflow for the development of a modular, multiplex molecular subty-
ping technique which can be implemented similarly for other pathogens monitored by 
the WIV-ISP. On the other hand, SalMolType also allowed for the introduction of the 
Luminex® technology in the WIV-ISP. The Luminex® technology paves the way to a broad 
range of proteomic and genomic applications, where multiplexing at both a high level 
and high-throughput, and with the same equipment, are within the range of possibilities. 
Researchers working on other ongoing research projects within the WIV-ISP are already 
developing Luminex® assays on the MAGPIX® platform, e.g. for detection of unautho-
rised genetically modified organisms (UGMs) in the food and feed chain (plants) in the 
UGMMONITOR project or for characterisation of shiga toxin-producing Escherichia coli 
in the IDESTEC project. Other applications of the Luminex® technology will be developed 
within the scope of the projects mycoMOLAIR (airborne fungi), epiURO (miRNA and 
DNA-methylation) and ORIENT-EXPRESS (orientation platform for pathogen and GMO).
Besides research projects in which a Luminex® assay is developed, the MAGPIX® plat-
form is also already being used to test commercially available kits in the fields of clinical 
diagnostics and life science research: the xTAG® Respiratory Viral Panel (RVP) Fast 
allows for the detection of 16 RNA viruses and their subtypes from patients suspected of 
respiratory tract infections, while the Bio-Plex Pro™ human cytokine panel is a 15-plex 
immunoassay (sandwich ELISA) used to measure cytokine levels.
From the above it is clear that the Luminex® platform is a versatile instrument that both 
serves and incites public health research.
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FIGURE
Figure 1- Multiplex ligation dependent amplification (LDA). Probes have a target-specific part (stri-
ped), a universal primer site (blue) and a TAG-sequence (red, yellow and purple). After a multiplex 
ligation reaction, a singleplex PCR is performed with universal primers, one of which is labelled with 
biotin. After hybridisation to xTAG® beads, a fluorescent label is introduced during an incubation with 
streptavidin-phycoerythrin (SAPE).
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TABLES
Feature Direct hybridisation ASPE LDA
Usage Unrelated sequences, SNPs, multiple polymorphisms
Detection of uncon-
served sequences
- Less stringent + Stringent + Stringent
Multiplex step - mPCR - mPCR + Ligation
Addition of marker - Redesign - Redesign + No redesign
Buffers - TMAC + Tm + Tm
Coupling of capture 
probe
- Yes + No + No
Hybridisation to beads - Optimise: 45-55°C + Standard: 37°C + Standard: 37°C
PCR amplicon - < 300 bp + all sizes + all sizes
Patent + No + No - Yes
Cost ± ++ ±
Total time + 3.5 hours ± 7 hours ± 6 hours
 
Feature VisualOMPTM + Thermo-
BLASTTM
PrimerPlex
Company DNA Software® PREMIER Biosoft





Addition of TAG sequences Copy-Paste Automatically 
Addition of existing sequences Copy-Paste 
Fasta or Genbank file 
Entrez
Copy-Paste 
Fasta or Genbank file 
Entrez 
SNPdb
Addition of existing oligos Copy-Paste  
Fasta or Genbank file
Copy-Paste 
Fasta or Genbank file
Modified oligos Possible Not possible
Specificity test ThermoBLAST BLAST
Secondary structure folding Taken into account Not included
Experiment conditions Detailed General 








Help files Extensive Extensive
Tutorial Extensive Limited
Licence Annual payment One-time payment
Annual maintenance fee
Table 1 - Overview of advantages (+) and disadvantages (-) of direct hybridisation, allele speci-
fic primer extension (ASPE) and ligation dependent amplification (LDA). mPCR: multiplex PCR; 
Tm: Tm buffer (0.1 M Tris-HCl pH 8, 0.2 M NaCl, 0.08% Triton® X-100); TMAC: tetramethylammo-
nium chloride buffer (3 M TMAC, 0.1% Sarkosyl, 50 mM Tris, 4 mM EDTA).
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Feature VisualOMPTM + Thermo-
BLASTTM
PrimerPlex
Company DNA Software® PREMIER Biosoft





Addition of TAG  
sequences
Copy-Paste Automatically 
Addition of existing 
sequences
Copy-Paste 
Fasta or Genbank file 
Entrez
Copy-Paste 
Fasta or Genbank file 
Entrez
SNPdb
Addition of existing oligos Copy-Paste 
Fasta or Genbank file
Copy-Paste 
Fasta or Genbank file
Modified oligos Possible Not possible
Specificity test ThermoBLAST BLAST
Secondary structure folding Taken into account Not included
Experiment conditions Detailed General 








Help files Extensive Extensive
Tutorial Extensive Limited
Licence Annual payment One-time payment
Annual maintenance fee
Table 2 - Comparison of software packages for multiplex oligonucleotide design and in silico simu-
lation of multiplex assays. ASPE: allele specific primer extension; LDA: ligation dependent amplifi-
cation.
